That is a good information source. Thanks. What

That is a good information source. Thanks. What the company will have to deal with is the fact that its core "nut" in a market economy for insured medical services (US mainly) has to be distinguished from the secondary and tertiary pay schemes in Europe, Canada, the UK and developing countries. It seems clear that regardless of the potential in the developing and subsidized health care worlds that NanoLogix must concentrate on the US and a few others because that is where the upfront $$ is. SE Asia and the Middle East are fine. The UN, WHO, foundations etc. are going to have to carry the freight in the developing world and that is a separate marketing track with different dynamics. The US situation is substantial and provides the core earnings. Given the scale of production we can be sure is required to satisfy anticipated demand I expect that NanoLogix even at this moment is dealing with outsourced production to generate the ability to satisfy emerging US markets.